SynthesisAmerican journal of respiratory and critical care medicine2020
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
Registry-linked trialOpen access · greenAbstract readSystematic Review
In one paragraph
Synthesis in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06253715 (Shortened Regimen for Drug-susceptible TB in Children), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Shortened Regimen for Drug-susceptible TB in Children
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Association of vitamin D receptor genetic variants with therapeutic response in multidrug-resistant pulmonary tuberculosis: a systematic review.Frontiers in cellular and infection microbiology · 2026Pooled it
- Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Pooled it
- Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy.Clinical pharmacokinetics · 2025Trial
- Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.Nature communications · 2024Trial
- Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.Antimicrobial agents and chemotherapy · 2022Trial
- Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Fixed-Dose Rifapentine-Isoniazid (1HP) for Tuberculosis Preventive Treatment in Chinese Adults: A Prospective Real-World Safety and Pharmacokinetic Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model.Clinical pharmacokinetics · 2026Article
- Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).Emerging microbes & infections · 2025Article
- Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection.Pharmaceutics · 2023Review
- Eradication of Drug-TolerantMicroorganisms · 2023Review
- New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.Respiration; international review of thoracic diseases · 2023Review
- A narrative review of tuberculosis in the United States among persons aged 65 years and older.Journal of clinical tuberculosis and other mycobacterial diseases · 2022Review
- Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study.BMJ open · 2022Article
- National approaches to TB care in adolescents.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Review
- Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling.Frontiers in pharmacology · 2022Article
- Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.Antimicrobial agents and chemotherapy · 2021Article
- Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.Journal of the International AIDS Society · 2021Article
- Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.The European respiratory journal · 2021Article
- Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention.American journal of respiratory and critical care medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 3 countries.
Jennifer E HibmaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California.
Kendra K RadtkeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California.
Susan E DormanSchool of Medicine, Johns Hopkins University, Baltimore, Maryland.
Amina JindaniSt. George's, University of London, London, United Kingdom.
Kelly E DooleySchool of Medicine, Johns Hopkins University, Baltimore, Maryland.
Marc WeinerDepartment of Medicine, University of Texas Health Science Center, San Antonio, Texas.
Helen M McIlleronDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Radojka M SavicDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California.
University of California, San Francisco · USJohns Hopkins University · USSt George's, University of London · GBThe University of Texas Health Science Center at San Antonio · USUniversity of Cape Town · ZA
Funding
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICST32GM007546 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Radojka Savic · 1985 to 2026
$8.9MPHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1MIdentifying Optimal Treatment Strategies for Tuberculosis TreatmentR01AI135124 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAND, DAVID, SAVIC, RADOJKA · 2019 to 2023
$3.8MNIAID NIH HHS R01 AI135124NIGMS NIH HHS T32 GM007175NIGMS NIH HHS T32 GM007546
Abstract
PubMed holds no abstract for this paper.
Indexed as
Dose-Response Relationship, DrugAdolescentAdultAgedAged, 80 and overAntibiotics, AntitubercularFemaleHumansLatent TuberculosisMaleMiddle AgedRifampinYoung AdultAntibiotics, AntitubercularRifampinrifapentinelatent tuberculosispopulation pharmacokineticsrifamycinsrifapentinetuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06253715ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.